TY - JOUR
T1 - Burkitt lymphoma after solid-organ transplant
T2 - Treatment and outcomes in the paediatric PTLD collaborative
AU - Afify, Zeinab
AU - Orjuela-Grimm, Manuela
AU - Smith, Christine Moore
AU - Dalal, Mansi
AU - Ford, James B.
AU - Pillai, Pallavi
AU - Robles, Joanna M.
AU - Reddy, Sonika
AU - McCormack, Sarah
AU - Ehrhardt, Matthew J.
AU - Ureda, Tonya
AU - Alperstein, Warren
AU - Edington, Holly
AU - Miller, Tamara P.
AU - Rubinstein, Jeremy D.
AU - Kavanaugh, Madison
AU - Bukowinski, Andrew J.
AU - Friehling, Erika
AU - Rivers, Julie M.
AU - Chisholm, Karen M.
AU - Marks, Lianna J.
AU - Mason, Clinton C.
N1 - Funding Information:
Clinton C. Mason acknowledges funding from the Paediatric Cancer Program, which is supported by the Intermountain Healthcare and Primary Children's Hospital Foundations as well as the Department of Paediatrics and Division of Paediatric Haematology/Oncology at the University of Utah.
Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2023/2
Y1 - 2023/2
N2 - Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL at 14 paediatric medical centres in the United States. Median age at organ transplantation was 2.0 years (range: 0.1–14) and age at PSOT-BL diagnosis was 8.0 years (range: 1–17). All but one patient had late onset of PSOT-BL (≥2 years post-transplant), with a median interval from transplant to PSOT-BL diagnosis of 4.0 years (range: 0.4–12). Heart (n = 18 [51.4%]) and liver (n = 13 [37.1%]) were the most frequently transplanted organs. No patients had loss of graft or treatment-related mortality. A variety of treatment regimens were used, led by intensive Burkitt lymphoma-specific French–American–British/Lymphomes Malins B (FAB/LMB), n = 13 (37.1%), and a low-intensity regimen consisting of cyclophosphamide, prednisone and rituximab (CPR) n = 12 (34.3%). Median follow-up was 6.7 years (range: 0.5–17). Three-year event-free and overall survival were 66.2% and 88.0%, respectively. Outcomes of PSOT-BL patients receiving BL-specific intensive regimens are comparable to reported BL outcomes in immunocompetent children. Multi-institutional collaboration is feasible and provides the basis of prospective data collection to determine the optimal treatment regimen for PSOT-BL.
AB - Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL at 14 paediatric medical centres in the United States. Median age at organ transplantation was 2.0 years (range: 0.1–14) and age at PSOT-BL diagnosis was 8.0 years (range: 1–17). All but one patient had late onset of PSOT-BL (≥2 years post-transplant), with a median interval from transplant to PSOT-BL diagnosis of 4.0 years (range: 0.4–12). Heart (n = 18 [51.4%]) and liver (n = 13 [37.1%]) were the most frequently transplanted organs. No patients had loss of graft or treatment-related mortality. A variety of treatment regimens were used, led by intensive Burkitt lymphoma-specific French–American–British/Lymphomes Malins B (FAB/LMB), n = 13 (37.1%), and a low-intensity regimen consisting of cyclophosphamide, prednisone and rituximab (CPR) n = 12 (34.3%). Median follow-up was 6.7 years (range: 0.5–17). Three-year event-free and overall survival were 66.2% and 88.0%, respectively. Outcomes of PSOT-BL patients receiving BL-specific intensive regimens are comparable to reported BL outcomes in immunocompetent children. Multi-institutional collaboration is feasible and provides the basis of prospective data collection to determine the optimal treatment regimen for PSOT-BL.
KW - Burkitt lymphoma
KW - lymphoproliferative disorder
KW - post-solid-organ transplantation
UR - http://www.scopus.com/inward/record.url?scp=85143402577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143402577&partnerID=8YFLogxK
U2 - 10.1111/bjh.18498
DO - 10.1111/bjh.18498
M3 - Article
C2 - 36454546
AN - SCOPUS:85143402577
SN - 0007-1048
VL - 200
SP - 297
EP - 305
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -